Relay Therapeutics, Inc. Shareholders' Equity
Relay Therapeutics, Inc. (RLAY) had Shareholders' Equity of $890.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $890.01M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $642.18M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $567.06M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $607.71M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $890.01M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $642.18M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $567.06M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $607.71M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $665.66M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $721.08M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $777.79M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $838.86M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $681.74M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $745.76M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $752.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $778.37M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $810.12M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $883.41M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $950.22M 10-K · filed 2026-02-26 |
| 2022-09-30 | $999.77M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $779.64M 10-Q · filed 2023-11-02 |
| 2022-03-31 | $841.97M 10-Q · filed 2023-11-02 |
| 2021-12-31 | $897.81M 10-K · filed 2025-02-26 |
| 2021-09-30 | $571.09M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $618.53M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $732.79M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $763.29M 10-K · filed 2024-02-22 |
| 2020-09-30 | $713.52M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$225.39M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$202.35M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$180.44M 10-K · filed 2023-02-23 |
| 2019-09-30 | -$158.29M 10-Q · filed 2020-11-12 |
| 2019-06-30 | -$140.02M 10-Q · filed 2020-11-12 |
| 2019-03-31 | -$124.16M 10-Q · filed 2020-11-12 |
| 2018-12-31 | -$110.93M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |